JPRN-jRCT1030210622进行中（未招募）未知
Assessment of tumor proportion for biomarker tests prior to the selection of first-line therapy in advanced non-squamous non-small cell lung cancer patients in the real world setting in Japan: a prospective, multicenter, observational study - ASTRAL study
Hiroshi Kitagawa0 个研究点目标入组 240 人开始时间: 2022年2月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Patient aged at least 20 years at the time of consent.
- •2.Pathologically confirmed non-squamous NSCLC.
- •3.Newly diagnosed, locally advanced (clinical stage IIIB, IIIC) or metastatic NSCLC (clinical stage IVA or IVB) or recurrent NSCLC (per Version 8 of the International Association for the Study of Lung Cancer [IASLC] Staging Manual in Thoracic Oncology), not amenable to curative surgery or radiotherapy
- •4.Treatment- naive for locally advanced/ metastatic/ recurrent NSCLC
- •5.Tumor cell proportion was assessed using FFPE samples and biomarker test was ordered within the period between diagnosis of locally advanced/ metastatic/ recurrent NSCLC and starting 1st line treatment.
- •6.Provision of informed consent prior to the start of 1st line therapy and any study specific procedures.
排除标准
- 未提供
研究者
相似试验
招募中
2 期
Examination of the usefulness as the tumor marker of the NY-ESO-1 antibody titer in the esophageal cancer patientesophageal cancerJPRN-UMIN000008997Osaka University,Graduate School of Medicine, Department of Gastroenterological Surgery400
招募中
2 期
Examination of the usefulness as the tumor marker of the NY-ESO-1 antibody titer in the stomach cancer patientgastric cancerJPRN-UMIN000007925Osaka University Clinical Research Group for Gastroenterological Study1,000
进行中（未招募）
不适用
Blood testing to predict good response to chemotherapyCTRI/2020/10/028763AIIMS
已完成
不适用
tudy on Biomarkers Using Circulating Tumor Cells When Administering Osimertinib in Patients with EGFR Mutation-positive Lung CancerJPRN-UMIN000032055Toho University50
已完成
不适用
CA209-759: Blood-borne biomarkers for tumor response to Nivolumab in KRAS-mutated non-small cell lung cancer, an exploratory studyNon-small cell lung cancer (NSCLC)10038666NL-OMON45880niversitair Medisch Centrum Groningen40